Natac increases its EBITDA by 66.5% in 2025, surpassing €23 million

Natac Natural Ingredients (NAT), a biotechnology company specializing in the sustainable production of botanical extracts and omega-3 oils, closed fiscal year 2025 with a strong improvement in profitability, recording a normalized EBITDA of over €23 million, representing a 66% increase compared to the €13.82 million achieved in 2024. This figure exceeds the €20 million previously forecasted and communicated to the market.

Regarding revenue, it nearly reached €48 million last year, 33% higher than the previous year, driven by organic growth, the acquisition of new clients, and greater operational efficiency.

“The 2025 results confirm that we have exceeded the profit forecasts communicated to the market, demonstrating the company’s profitability. Over the past 12 months, we have been able to scale the business while maintaining operational discipline and strengthening our competitive position in the market,” highlights Antonio Delgado, CEO of Natac.

For the current fiscal year, the company expects to surpass €68 million in revenue and reach a normalized EBITDA of €26 million.

Capital Increase
Natac has been undergoing a strategic review process since last July. Although the entry of a majority investor was initially considered, this option has been put on hold to prioritize inorganic growth through the acquisition of companies in the sector that provide strategic value to the group.

In this context, and to support this strategy, Natac’s Board of Directors has agreed to propose to the General Shareholders’ Meeting, which will be held in the coming days, a capital increase with pre-emptive subscription rights for a maximum amount of €35 million, at an issue price of €0.75 per share.

The success of the operation is guaranteed, as Natac’s reference shareholders have expressed their commitment to subscribe to the available tranches.